ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
5.07
+0.36 (7.64%)
At close: Nov 20, 2024, 4:00 PM
4.860
-0.210 (-4.14%)
After-hours: Nov 20, 2024, 6:22 PM EST
Company Description
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound.
The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
ENDRA Life Sciences Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | May 9, 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Alexander Tokman |
Contact Details
Address: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105-1570 United States | |
| Phone | 734 335 0468 |
| Website | endrainc.com |
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B104 |
| ISIN Number | US29273B3024 |
| Employer ID | 26-0579295 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Alexander Y. Tokman | Acting Chief Executive Officer and Chairman |
| Michael Thornton Ph.D. | Chief Technology Officer |
| Dr. Jonathan Behr Ph.D. | Co-Founder |
| Richard Jacroux | Chief Financial Officer and Secretary |
| Steve Freeman | Human Resources Leader |
| Ziad Rouag | Head of Regulatory and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 16, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 6, 2024 | PRE 14A | Other preliminary proxy statements |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 23, 2024 | 8-K | Current Report |